German fraud net widens
This article was originally published in Clinica
Investigations into alleged backhanders to German doctors and technicians have widened to include 2,700 individuals at more than 460 hospitals in all German Lander. Prosecutors had begun by looking at 70 staff at 60 heart clinics (see Clinica No 648, p 1).
You may also be interested in...
China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.